4:20 PM
 | 
Apr 26, 2019
 |  BC Extra  |  Company News

Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

Editor's Note: This article was updated on May 01, 2019 at 1:36 PM PDT

Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 preferred formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs.

PBMs and insurance companies typically require manufacturers pay rebates to secure inclusion or a favorable position on formularies. The biopharma industry has argued that high list prices are required to make large rebates possible, increasing out-of-pocket...

Read the full 305 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >